Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
Bhalla A, Ravi R, Fang M, Arguello A, Davis SS, Chiu CL, Blumenfeld JR, Nguyen HN, Earr TK, Wang J, Astarita G, Zhu Y, Fiore D, Scearce-Levie K, Diaz D, Cahan H, Troyer MD, Harris JM, Escolar ML. Bhalla A, et al. Among authors: fiore d. Int J Mol Sci. 2020 Jul 22;21(15):5188. doi: 10.3390/ijms21155188. Int J Mol Sci. 2020. PMID: 32707880 Free PMC article.
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, Buffels R, Fiore D, Garren H, Han J, Hauser SL. Turner B, et al. Among authors: fiore d. J Neurol. 2019 May;266(5):1182-1193. doi: 10.1007/s00415-019-09248-6. Epub 2019 Feb 28. J Neurol. 2019. PMID: 30820738 Free PMC article. Clinical Trial.
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Fox EJ, Markowitz C, Applebee A, Montalban X, Wolinsky JS, Belachew S, Fiore D, Pei J, Musch B, Giovannoni G. Fox EJ, et al. Among authors: fiore d. Mult Scler. 2018 Dec;24(14):1862-1870. doi: 10.1177/1352458518808189. Epub 2018 Nov 12. Mult Scler. 2018. PMID: 30415593 Free PMC article. Clinical Trial.
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL, Calabresi PA, Kieseier BC, Liu S, You X, Fiore D, Hung S. Arnold DL, et al. Among authors: fiore d. BMC Neurol. 2017 Feb 10;17(1):29. doi: 10.1186/s12883-017-0799-0. BMC Neurol. 2017. PMID: 28183276 Free PMC article. Clinical Trial.
Fluorescently Tagged Poly(methyl methacrylate)s.
Grisi F, Troiano R, Fiore D, Gazzerro P, Lettieri M, Venditto V, Pragliola S. Grisi F, et al. Among authors: fiore d. Molecules. 2024 Dec 16;29(24):5940. doi: 10.3390/molecules29245940. Molecules. 2024. PMID: 39770029 Free PMC article.
298 results